anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method of extracting pharmacologically active compounds from cannabis biomass is disclosed. The method comprises providing a raw biomass containing target compounds. Slurry is prepared by adding a solvent to the prepared biomass. In a preferred embodiment, the solvent may be a medium-chain triglyceride, such as coconut oil, or an edible and food-grade solvent or emulsifier used to standardize active compounds in pharmaceutical, nutraceutical, functional food, or cosmetic formulations. In some embodiments, the solvent may be a polyunsaturated fatty acid (PUFA), com oil, safflower oil, borage oil, flax oil, canola oil, cottonseed oil, soybean oil, olive oil, sunflower oil, monoglycerides, diglycerides, triglycerides, lecithin, limonene, essential oils of spices, herbs or other plants, fish oil, glycerol, glycols, or any other, or mixtures thereof. Various pharmacologically active compounds could be extracted from the slurry by processing in a continuous flow extractor. Successively, the solvent containing various pharmacologically active compounds may be separated from a spent biomass.
Plasma Protein and Erythrocyte Binding: Cilostazol is 95%-98% protein bound, predominantly to albumin. The mean percent binding for 3,4-dehydro-cilostazol is 97.4% and for 4´-trans-hydroxy-cilostazol is 66%. Mild hepatic impairment did not affect protein binding. The free fraction of cilostazol was 27% higher in subjects with renal impairment than in normal volunteers. The displacement of cilostazol from plasma proteins by erythromycin, quinidine, warfarin, and omeprazole was not clinically significant.

Metabolism and Excretion:  
Cilostazol is eliminated predominately by metabolism and subsequent urinary excretion of metabolites. Based on in vitro studies, the primary isoenzymes involved in cilostazol's metabolism are CYP3A4 and, to a lesser extent, CYP2C19. The enzyme responsible for metabolism of 3,4-dehydro-cilostazol, the most active of the metabolites, is unknown.

Following oral administration of 100 mg radiolabeled cilostazol, 56% of the total analytes in plasma was cilostazol, 15% was 3,4-dehydro-cilostazol (4-7 times as active as cilostazol), and 4% was 4´-trans-hydroxy-cilostazol (one fifth as active as cilostazol). The primary route of elimination was via the urine (74%), with the remainder excreted in feces (20%). No measurable amount of unchanged cilostazol was excreted in the urine, and less than 2% of the dose was excreted as 3,4-dehydro-cilostazol. About 30% of the dose was excreted in urine as 4´-trans-hydroxy-cilostazol. The remainder was excreted as other metabolites, none of which exceeded 5%. There was no evidence of induction of hepatic microenzymes.
Octreotide acetate injection may be administered subcutaneously or intravenously. Subcutaneous injection is the usual route of administration of octreotide acetate injection for control of symptoms. Pain with subcutaneous administration may be reduced by using the smallest volume that will deliver the desired dose. Multiple subcutaneous injections at the same site within short periods of time should be avoided. Sites should be rotated in a systematic manner. 

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if particulates and/or discoloration are observed. Proper sterile technique should be used in the preparation of parenteral admixtures to minimize the possibility of microbial contamination. Octreotide acetate injection is not compatible in Total Parenteral Nutrition (TPN) solutions because of the formation of a glycosyl octreotide conjugate which may decrease the efficacy of the product.

Octreotide acetate injection is stable in sterile isotonic saline solutions or sterile solutions of dextrose 5% in water for 24 hours. It may be diluted in volumes of 50 to 200 mL and infused intravenously over 15 to 30 minutes or administered by IV push over 3 minutes. In emergency situations (e.g., carcinoid crisis), it may be given by rapid bolus. 

The initial dosage is usually 50 mcg administered twice or three times daily. Upward dose titration is frequently required. Dosage information for patients with specific tumors follows.
Three blood samples will be taken at day 1, month 3 and month 6. A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.
Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab SC in maintenance phase. Vedolizumab SC, 108 mg, injection, Q2W and placebo-matching IV infusions, Q8W, starting at Week 6 up to approximately Week 50.
Focalin has a high potential for abuse and misuse. The use of Focalin exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Focalin can be diverted for non-medical use into illicit channels or distribution [see Drug Abuse and Dependence (9.2)]. Misuse and abuse of CNS stimulants, including Focalin, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Before prescribing Focalin, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store Focalin in a safe place, preferably locked, and instruct patients to not give Focalin to anyone else. Throughout Focalin treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
This phase II study is designed to assess the toxicity profile and the proportion of overall response in patients with relapsed or refractory WM. This will study the effect of single agent LBH589 on response in these patients. Efficacy measures will include both objective clinical measurements and investigator-reported outcomes. Response and time to event analyses will follow the criteria set forth in the International Waldenstrom consortium recommendations. Prior to the start of the study, investigators will assess disease and perform a CT scan of the chest, abdomen and pelvis.

Response will be assessed after 2 cycles. If patients have stable disease or response, then they will continue on therapy until progression or unacceptable toxicity, being assessed every cycle until the sixth cycle and then every 3 months. Patients who show progression after 2 cycles will come off therapy and undergo event monitoring every 3 months. All responses will be assessed by M-protein quantification and immunofixation from serum and IgM monoclonal protein level. In addition, BM biopsies will be done at baseline, at the end of cycle 6 and at the end of all therapy. The protocol was amended because of concerns of toxicity to allow a starting dose of 25 mg; 12/36 (33%) patients were enrolled on the 25 mg dose.
This clinical trial will evaluate the development, implementation, and impact of a central kitchen preparing and serving meals to child care centers in rural Harnett County, North Carolina. The goals of the kitchen are to improve meal quality, reduce workload on child care providers, create a sustainable business model, and provide a source of community economic development. Our evaluation of the Sandhills Central Community Kitchen is important to better understand how this model can be replicated to serve rural communities. We will recruit 20 child care centers (10 intervention and 10 as a control group); we estimate that each child care center will serve 40 children. We will collect baseline data at the beginning of the project from all 20 centers, and will repeat data collection at the end of the project to assess changes. Data will be collected through parent surveys, surveys and interviews with child care center directors, surveys and focus groups with teachers, interviews with the church pastor and community leaders where the kitchen is based, surveys of kitchen staff, nutritional analysis of menu data, collection and analysis of food costs, and through use of the "Veggie Meter" (a non-invasive instrument that assesses changes in intake of fruits and vegetables by measuring skin carotenoids) with child care center children and staff. Our goal is to document the impacts of central kitchens in terms of nutritional and economic benefits in order to create a replicable model.

Skin carotenoid status (SCS) will be used to measure F\&V intake among pre-schoolers. Carotenoids, the colorful phytonutrients found in vegetables are correlated with F\&V intake. A higher carotenoid level is correlated with higher F\&V intake; conversely lower carotenoid levels are associated with lower F\&V intake over the past month. To measure carotenoid level, researchers will use the Veggie Meter®. The Veggie Meter is a small, portable, non-invasive device that assesses SCS via pressure-mediated reflection spectroscopy. This is more accurate than self-reported diet among children.
The participants of this study are working age female patients from the Central Finland Health Care District, and who have been treating because of severe pain. After eligibility has been assessed by health-related questionnaire and clinical examination, the participants will be randomly assigned into the treatment or control group. Treatment group patients will receive the loan activated BEMER-care unit, while controls will receive inactivated sham BEMER-unit. All participants will use the device regularly on a daily bases over three months. After one month treatment break, the treatment group will become a control group and control group will become a treatment group according cross-over design principle. Switching the groups will take place by changing the BEMER devices during the break. Throughout the study, both participants and researchers are unaware whether the participants are using activated or inactivated BEMER-devices. The research will be carried out and coordinated by Central Finland Central Hospital, and the research project will take place between September 2014 and June 2018.
This invention relates to methods for preparing cyclic peptides and peptidomimetic compounds in solution and bound to solid supports, and to cyclic peptide or peptidomimetic libraries for use in drug screening programmes. In particular the invention relates to a generic strategy for synthesis of cyclic peptides or peptidomimetics which enables the efficient synthesis under mild conditions of a wide variety of desired compounds. We have examined two approaches: 1) Positioning reversible N-amide substituents in the sequence. 2) Applying native ligation chemistry in an intramolecular sense. We have evaluated these for their improvements in the solution and solid phase synthesis of small cyclic peptides. We have systematically investigated the effects of preorganising peptides prior to cyclisation by using peptide cyclisation auxiliaries, and have developed new linkers to aid cyclic peptide synthesis. We have found surprising improvements in both yields and purity of products compared to the prior art methods. The combination of these technologies provides a powerful generic approach for the solution and solid phase synthesis of small cyclic peptides. We have also developed linkers and peptide cyclisation auxiliaries to aid cyclic peptide synthesis. The ring contraction and N-amide substitution technology of the invention provide improved methods for the synthesis of cyclic peptides and peptidomimetics.  When used in conjunction with linker strategies, this combination provides solid-phase avenues to cyclic peptides and peptidomimetics.
Major depressive disorder (MDD) is a common and serious psychiatric illness. It is among the leading causes of disability and is the psychiatric disorder most often associated with suicide. The treatment of MDD with antidepressant medication remains largely trial and error. Little empirical evidence exists to guide the treatment of MDD when suicide risk is a major factor. Selective serotonin reuptake inhibitors (SSRIs) are a type of antidepressant medication that works by increasing the amount of serotonin, a natural substance in the brain that helps maintain mental balance. The study compared the effectiveness of paroxetine, an SSRI, versus bupropion, a non-SSRI, on suicidal ideation and/or behavior in depressed patients with a past suicide attempt and/or current suicidal thoughts. Results of the completed primary study have been published (Grunebaum MF et al. Neuropsychopharmacology. 2012 Feb;37(3):697-706).

In the ongoing secondary neuro-imaging component of the study, Participants are randomly assigned to either paroxetine or bupropion treatment for 8 weeks with fMRI scans involving a reward processing task at baseline and Week 8. Weekly study visits include interviews with a psychologist, self-report scales, and medication monitoring. All participants will then be offered 4 additional months of open clinical treatment. If original medication assignments prove to be ineffective, participants will have the option to switch to another medication. After completing the study, participants will be referred for ongoing treatment.
Transcranial direct current stimulation (tDCS) and intermittent theta burst stimulation (iTBS) were both demonstrated to have therapeutic potentials to rapidly induce neuroplastic effects in various rehabilitation training regimens. Recently, the investigators have developed a novel transcranial electrostimulation device that can flexibly output an electrical current with combined tDCS and iTBS waveforms. However, limited studies have determined the therapeutic effects of this special waveform combination on clinical rehabilitation. Herein, the investigators aiming to brain stimulation effects of tDCS-iTBS on upper-limb motor function in chronic stroke patients.

Twenty-four subjects with a chronic stroke were randomly assigned to a real non-invasive brain stimulation (NIBS; subjects received the real tDCS+iTBS output) group or a sham NIBS (subjects received sham tDCS+iTBS output) group. All subjects underwent 1 h treatment of a conventional rehabilitation program (3 days a week for 6 weeks), where a 20-min NIBS intervention was simultaneously applied during conventional rehabilitation. Outcome measures were assessed before and immediately after the intervention period: Fugl-Meyer Assessment-Upper Extremity (FMA-UE), Jebsen-Taylor Hand Function Test (JTT), and Finger-to-Nose Test (FNT).
PURPOSE:To obtain a remedy, consisting of SHOSAIKOTO GO KEISHI KA SHAKUYAKUTO [a mixture of SHOSAIKOTO (decoction of Bupleurum Radix, Pinneliae Tuber, etc.) with KEISHI (Cinnamomi Cortex) added to SHAKUYAKUTO (decoction of Poeny Radix, etc.)] and effective against psychotic and neurotic symptoms caused by cerebral angiopathy. CONSTITUTION:An improver obtained by extracting 5-8pts.wt. Bulpeurum Radix, 4-7pts.wt. Poeny Radix, 4-5pts.wt. Pinelliae Tuber, 3-5pts.wt. Cinammomi Cortex, 3-5pts.wt. Zizyphi Inermi Fructus, 2-4pts.wt. Scutellaria Radix, 2-4pts.wt. Ginseng Radix, 1-3pts.wt. Glycyrrhizae Radix and 0.5-2pts. wt. Zinziber officinale Roscoe with water in an amount of 10 times while hot, filtering the resultant extract, drying the obtained filtrate to provide dried extract powder of SHOSAIKOTO GO KEISHI KA SHAKUYAKUTO and preparing the aimed pharmaceutical according to a conventional method. The above-mentioned pharmaceutical is preferably administered in an amount of 3-15g expressed in terms of dried weight of the active ingredients in several divided portions a day.
INTRODUCTION: Weight stigma is widespread and exists across numerous domains including health care, educational institutions, workplaces, mass media, and interpersonal relationships. Weight stigma experienced during the college years may be particularly consequential because the college years are a period of increased vulnerability for the development of mental health concerns. The purpose of the present study was to examine how experiences of weight stigma relate to mental health concerns, including symptoms of eating disorders, anxiety, and depression, among college students.
METHODS: Prevalence of interpersonal and anticipated weight stigma was examined among 2,707 students participating in the 2018-2019 and 2019-2020 Healthy Minds Study and tested for differences in prevalence across student characteristics. Logistic regression was used to explore relationships between measures of weight stigma and student mental health. Analyses were conducted in 2021-2023.
RESULTS: Interpersonal and anticipated weight stigma were reported by 12.3% and 15.3% of students, respectively. Experiences of interpersonal and anticipated weight stigma were generally lowest among cisgender male students, heterosexual students, those with the fewest financial concerns, and those who did not perceive themselves to be "overweight." Both interpersonal and anticipated weight stigma were associated with elevated odds of high weight concerns, past-month binge eating, past-month purging, high eating disorder risk, moderate/severe anxiety symptoms, and moderate/severe depressive symptoms.
CONCLUSIONS: Findings implicate interpersonal and anticipated weight stigma as potential risk factors for a range of mental health concerns. Weight stigma is an under-recognized and under-funded public health problem.
Disclosed are an apparatus and a method for producing a freeze-dried facial mask. The apparatus for producing a freeze-dried facial mask comprises a first load wheel (100), a second load wheel (200), a solution application assembly (300), a quick-freezing assembly (400) and a drying assembly (500). A roll of cloth for the facial mask is wound on one of the first load wheel (100) and the second load wheel (200), and can be moved to wind onto the other. The roll of cloth between the first load wheel (100) and the second load wheel (200) can be moved past the solution application assembly (300) and the quick-freezing assembly (400) sequentially in a first direction, and can be moved past the drying assembly (500) in a second direction. The solution application assembly (300) is configured to apply a solution onto the roll of cloth. The quick-freezing assembly (400) is configured to freeze the roll of cloth after solution application. The drying assembly (500) is configured to dry the frozen roll of cloth. The first direction is opposite to the second direction. The apparatus for producing a freeze-dried facial mask addresses the technical problem in which a prior art production apparatus occupies a large space.
BACKGROUND: Individuals with end-stage renal disease (ESRD) and fingertip wounds are at high risk of poor wound healing, ultimately requiring amputations. Optimal performance of upper extremity amputation (UEA) in patients with ESRD is important to decrease complications and minimize total operative procedures needed. This study evaluated outcomes of UEA in patients with ESRD and described risk factors predisposing patients to complications.
METHODS: A retrospective analysis of patients receiving nontraumatic UEA for fingertip wounds was conducted, stratified by patients with and without ESRD. Demographics, comorbidities, complications, and hospital course were analyzed between groups for differences. Subanalysis of patients with ESRD was conducted to characterize operative course and predictors of complications.
RESULTS: A total of 132 patients were included, 106 controls and 26 with ESRD. Compared with controls, patients with ESRD required more amputations (P < .001) and total operations (P < .001) to achieve wound healing. Patients with ESRD experienced higher rates of postoperative complications (P < .001). Predictors for complications in patients with ESRD were comorbid diabetes (odds ratio [OR]: 45; 95% confidence interval [CI], 1.7-1226.9), vascular disease (OR: 30; 95% CI, 2-441.8), arterial calcification (OR: 18; 95% CI, 1.56-207.5), and presence of a hemodialysis shunt in the affected arm (OR: 18; 95% CI, 1.56-207.5). Within patients with ESRD, initial amputation at, or proximal to, the metacarpophalangeal joint (MCPJ) led to fewer amputations (1.2 vs 2.19, P = .04) and fewer total operative procedures (4.1 vs 6.6, P = .03), compared with initial amputation distal to the MCPJ.
CONCLUSION: In nontraumatic fingertip wounds, patients with ESRD had worse operative outcomes than patients without ESRD. More aggressive management of fingertip wounds using earlier and more proximal initial amputations may expedite wound healing in certain high-risk patients with ESRD.
The Epigravettian human remains from Riparo Tagliente in northern Italy represent some of the earliest evidence of human occupation in the southern Alpine slopes after the Last Glacial Maximum. Genomic analyses of the 17,000-year-old Tagliente 2 mandible revealed the oldest presence of a genetic profile with affinities to the Near East in the Italian peninsula, which later became the most widespread hunter-gatherer ancestry across Europe. However, a comparable biomolecular characterization of the Tagliente 1 burial remains unavailable, preventing us from defining its biological relationships with Tagliente 2. Here, we apply paleogenomic, isotopic, and radiocarbon dating analyses on a femur fragment of Tagliente 1 and compare the reconstructed data with previously reported results from Tagliente 2. Despite their different isotopic signatures and non-overlapping radiocarbon dates, we reveal that the two human remains belong to the same male individual. We determine that the distinct isotopic values can be explained by different dietary practices during lifetime, whereas the non-overlapping radiocarbon dates can be caused by minimal radiocarbon contamination, possibly deriving from chemical treatments for conservation purposes. These findings highlight the importance of interdisciplinary biomolecular studies in offering new perspectives on the Palaeolithic fossil record and addressing long-standing bioarchaeological questions.
Treatment sequence BCADE is applied. The 5 treatments were separated by a washout period of at least 5 days.